Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Christopher Morrow

Showing results (11-20 of 13) with videos related to

Pageof 2
Sort By:
You have reached the last page of results.This site can display upto 13 results.
Cancer Discovery|December 18, 2016
Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER AntagonistsWeiyi Toy, Hazel Weir, Pedram Razavi, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Pageof 2

Showing results (11-20 of 13) with videos related to

Sort By:
Pageof 2
You have reached the last page of results.This site can display upto 13 results.
Cancer Discovery|December 18, 2016
Activating <i>ESR1</i> Mutations Differentially Affect the Efficacy of ER AntagonistsWeiyi Toy, Hazel Weir, Pedram Razavi, et al.
The Lancet. Oncology|July 13, 2026
Switching to camizestrant at ESR1 mutation emergence before disease progression during first-line treatment of hormone receptor-positive advanced breast cancer (SERENA-6): extended analysis of a double-blind, placebo-controlled, randomised, phase 3 trialNicholas C Turner, Erica L Mayer, Yeon Hee Park, et al.
Molecular Oncology|December 6, 2021
Serial monitoring of genomic alterations in circulating tumor cells of ER-positive/HER2-negative advanced breast cancer: feasibility of precision oncology biomarker detectionAndi K Cani, Emily M Dolce, Elizabeth P Darga, et al.
Pageof 2